VISTECH grant for Anadis
Tuesday, 01 July, 2008
Melbourne's Anadis (ASX: ANX) has been awarded a significant grant from VISTECH for its alimentary mucositis treatment.
The grant is one of only three awarded from VISTECH, a bi-national fund granted by the Victorian and the Israeli Governments, and was awarded through a competitive process including a vigorous scientific assessment.
The US$500,000 grant was awarded to Anadis and its Israeli collaborator Maya BioTech. The money will be used to help fund a clinical trial of polyclonal antibodies, which is expected to take between 18-24 months.
Anadis is predicting to be able to launch a commercial product in as little as two years.
Gastro-intestinal and oral mucositis is a significant side effect of cancer therapy.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
